US9453006 — Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient

USPTO Abstract

Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that I (011) with respect to a sum total of I (001) , I (100) , I (10-1) , I (011) , I (110) , I (11-1) , I (10-2) , I (11-2) , I (020) , I (021) , I (20-2) , I (121) , I (013) , I (11-3) , and I (221) is not less than 25%, provided that integrated intensities of diffraction peaks, which correspond to the (001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as I (001) , I (100) , I (10-1) , I (011) , I (110) , I (11-1) , I (10-2) , I (11-2) , I (020) , I (021) , I (20-2) , I (121) , I (013) , I (11-3) , and I (221) respectively in relation to the diffraction peaks detected in a range of 2θ=5 to 35° in a powder X-ray diffractometry using CuKα radiation.